All Title Author
Keywords Abstract

Elevated Serum Levels of Homocysteine as an Early Prognostic Factor of Psychiatric Disorders in Children and Adolescents

DOI: 10.1155/2012/373261

Full-Text   Cite this paper   Add to My Lib


Background and Goal. The aim was to examine the serum levels of homocysteine (Hcy) and their associations with the methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism in patients with schizophrenia and mood disorders as well as controls. Materials and Methods. There were 198 patients: 82 with schizophrenia spectrum disorders, 22 with mood disorders, and 94 controls. The level of Hcy was determined by an isocratic high-performance liquid chromatography system. MTHFR C677T polymorphism was analysed using the restriction fragment length polymorphism-polymerase chain reaction method. Results. The average level of Hcy was μmol/L for patients with schizophrenia, μmol/L for patients with affective disorders, versus μmol/L in a control. The highest level of Hcy has been observed in patients with episodic-recurrent course of schizophrenia ( μmol/L), paranoid schizophrenia continuous ( μmol/L), and in patients with affective disorders ( μmol/L). An association between the MTHFR gene C677T polymorphism and Hcy level was found by linear regression analysis ( , ). Conclusions. The data indicate a link between Hcy levels and schizophrenia and mood disorders. No associations between the level of Hcy in patients with schizophrenia and mood disorders and the MTHFR C677T polymorphism were found. 1. Introduction Hcy was first described by Butz and du Vigneud in 1932 [1]. They obtained the product by treating methionine with a concentrated acid. Three enzymes are directly involved in the Hcy metabolism: methionine synthase (MS), betaine homocysteine methyltransferase, and cystathionine β-synthase. Several other enzymes are indirectly involved. Vitamins B6 and B12 are cofactors to these enzymes, and folate is a substrate in the MS-mediated reaction [2]. Deficiencies in vitamins B6, B12, and folate can lead to high Hcy levels. Supplementation with pyridoxine, folic acid, B12, or folic acid, respectively, reduces the concentration of Hcy in the bloodstream. Methionine is the immediate precursor of S-adenosylmethionine, the methyl donor of numerous methylation reactions in the brain, including many that are directly involved in the synthesis and metabolism of monoamines such as dopamine, norepinephrine, and serotonin [3]. This suggests that an association between elevated Hcy and schizophrenia is biologically plausible. Another way of investigating the association between Hcy and mental disorders is via the MTHFR gene. MTHFR converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is needed for the remethylation of Hcy to methionine [4]. MTHFR


[1]  J. D. Finkalstein, “Homocysteine: a history in progress,” Nutrition Reviews, vol. 58, pp. 193–204, 2000.
[2]  C. Bolander-Gouaille and T. Bottiglieri, Homocysteine Related Vitamins and Neuropsychiatric Disorders, Springer, Paris, France, 2nd edition, 2007.
[3]  T. Bottiglieri, M. Laundy, R. Crellin, B. K. Toone, M. W. P. Carney, and E. H. Reynolds, “Homocysteine, folate, methylation, and monoamine metabolism in depression,” Journal of Neurology Neurosurgery and Psychiatry, vol. 69, no. 2, pp. 228–232, 2000.
[4]  M. Klerk, P. Verhoef, R. Clarke, H. J. Blom, F. J. Kok, and E. G. Schouten, “MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis,” Journal of the American Medical Association, vol. 288, no. 16, pp. 2023–2031, 2002.
[5]  A. Coppen and C. Bolander-Gouaille, “Treatment of depression: time to consider folic acid and vitamin B 12,” Journal of Psychopharmacology, vol. 19, no. 1, pp. 59–65, 2005.
[6]  J. W. Muntjewerff, R. S. Kahn, H. J. Blom, and M. Den Heijer, “Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis,” Molecular Psychiatry, vol. 11, no. 2, pp. 143–149, 2006.
[7]  B. Kempisty, A. Bober, M. ?uczak et al., “Distribution of 1298A > C polymorphism of methylenetetrahydrofolate reductase gene in patients with bipolar disorder and schizophrenia,” European Psychiatry, vol. 22, no. 1, pp. 39–43, 2007.
[8]  C. J. Murray and A. D. Lopez, The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Disease, Injuries and Risk Factors in 1990, Harvard School of Publics Health, Boston, Mass, USA, 1996.
[9]  A. S. Brown, T. Bottiglieri, C. A. Schaefer et al., “Elevated prenatal homocysteine levels as a risk factor for schizophrenia,” Archives of General Psychiatry, vol. 64, no. 1, pp. 31–39, 2007.
[10]  A. V. Makhro, E. R. Bulygina, and A. A. Boldyrev, “Effects of homocysteine and homocysteinic acid on cerebellar granule cells,” Neurochemical Journal, vol. 1, no. 2, pp. 127–132, 2007.
[11]  S. A. Lipton, W. K. Kim, Y. B. Choi et al., “Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 11, pp. 5923–5928, 1997.
[12]  A. Friedman, D. Kaufer, J. Shemer, I. Hendler, H. Soreq, and I. Tur-Kaspa, “Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response,” Nature Medicine, vol. 2, no. 12, pp. 1382–1385, 1996.
[13]  J. Levine, B. A. Sela, Y. Osher, and R. H. Belmaker, “High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 29, no. 7, pp. 1181–1191, 2005.
[14]  L. J. Ninger, “Homocysteine as a Risk Factor for Disease. Life Extension Magazine,” 2006,
[15]  Y. Osher, B. A. Sela, J. Levine, and R. H. Belmaker, “Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration,” Bipolar Disorders, vol. 6, no. 1, pp. 82–86, 2004.
[16]  ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research,
[17]  C. Marinho, I. Alho, D. Arduíno, L. M. Falc?o, J. Brás-Nogueira, and M. Bicho, “GST M1/T1 and MTHFR polymorphisms as risk factors for hypertension,” Biochemical and Biophysical Research Communications, vol. 353, no. 2, pp. 344–350, 2007.
[18]  A. Grieco, “Homocystinuria: pathogenetic mecanisms,” American Journal of the Medical Sciences, vol. 273, no. 2, pp. 120–132, 1977.
[19]  V. V. Kovalev, Psychiatry of Childhood, Medicina, Moscow, Russia, 1979.
[20]  F. M. Ausubel, Current Protocols in Molecular Biology, New Yourk, NY, USA, 1st edition, 1987.
[21]  B. J. Sadock and V. A. Sadock, Synopsis of Psychiatry, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 10th edition, 2007.
[22]  A. S. Tiganov, Manual of Psychiatry, vol. 1, Medicina, Moscow, Russia, 1999.
[23]  R. Goodman and S. Scott, Child Psychiatry, Blackwell Science, 1997.
[24]  G. L. Cantoni, “S-Anenysylmethionine: a new intermediate formed enzymatically from 1—methionine and adenosine triphosphate,” Journal of Biological Chemistry, vol. 204, pp. 403–416, 1953.
[25]  R. Rozen, “Molecular genetics of methylenetetrahydrofolate reductase deficiency,” Journal of Inherited Metabolic Disease, vol. 19, no. 5, pp. 589–594, 1996.
[26]  A. M. Molloy, S. Daly, J. L. Mills et al., “Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations,” The Lancet, vol. 349, no. 9065, pp. 1591–1593, 1997.
[27]  A. Reif, B. Pfuhlmann, and K. P. Lesch, “Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 29, no. 7, pp. 1162–1168, 2005.
[28]  G. A. Nevo, S. Meged, B. A. Sela, A. Hanoch-Levi, R. Hershko, and A. Weizman, “Homocysteine levels in adolescent schizophrenia patients,” European Neuropsychopharmacology, vol. 16, no. 8, pp. 588–591, 2006.


comments powered by Disqus